BIOMAT Database Logo BIOMAT Database Logo

[Difficulties of investigation of antibodies against human immunodeficiency virus type 2 using ELISA]. 1988

V Soriano Vázquez, and A Ribera Crusafont, and J Tor Aquilera, and R Muga Bustamante

UI MeSH Term Description Entries
D003429 Cross Reactions Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen. Cross Reaction,Reaction, Cross,Reactions, Cross
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015483 HIV Antibodies Antibodies reactive with HIV ANTIGENS. AIDS Antibodies,HIV-Associated Antibodies,HTLV-III Antibodies,HTLV-III-LAV Antibodies,LAV Antibodies,Lymphadenopathy-Associated Antibodies,T-Lymphotropic Virus Type III Antibodies, Human,HIV Associated Antibodies,HTLV III Antibodies,HTLV III LAV Antibodies,Lymphadenopathy Associated Antibodies,T Lymphotropic Virus Type III Antibodies, Human,Antibodies, AIDS,Antibodies, HIV,Antibodies, HIV Associated,Antibodies, HIV-Associated,Antibodies, HTLV III,Antibodies, HTLV-III,Antibodies, HTLV-III-LAV,Antibodies, LAV,Antibodies, Lymphadenopathy Associated,Antibodies, Lymphadenopathy-Associated
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015498 HIV-2 An HIV species related to HIV-1 but carrying different antigenic components and with differing nucleic acid composition. It shares serologic reactivity and sequence homology with the simian Lentivirus SIMIAN IMMUNODEFICIENCY VIRUS and infects only T4-lymphocytes expressing the CD4 phenotypic marker. HTLV-IV,Human T-Lymphotropic Virus Type IV,Human immunodeficiency virus 2,LAV-2,HIV-II,Human Immunodeficiency Virus Type 2,Human T Lymphotropic Virus Type IV,Immunodeficiency Virus Type 2, Human,SBL-6669

Related Publications

V Soriano Vázquez, and A Ribera Crusafont, and J Tor Aquilera, and R Muga Bustamante
Competition ELISA using a human monoclonal antibody for detection of antibodies against human immunodeficiency virus type 1.
April 1991, Journal of virological methods,
V Soriano Vázquez, and A Ribera Crusafont, and J Tor Aquilera, and R Muga Bustamante
Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120.
June 1995, Journal of virology,
V Soriano Vázquez, and A Ribera Crusafont, and J Tor Aquilera, and R Muga Bustamante
Protection against human immunodeficiency virus type 2 and simian immunodeficiency virus in macaques vaccinated against human immunodeficiency virus type 2.
March 1996, AIDS research and human retroviruses,
V Soriano Vázquez, and A Ribera Crusafont, and J Tor Aquilera, and R Muga Bustamante
Monoclonal antibodies against human immunodeficiency virus (HIV) type 2 core proteins: cross-reactivity with HIV type 1 and simian immunodeficiency virus.
September 1988, Proceedings of the National Academy of Sciences of the United States of America,
V Soriano Vázquez, and A Ribera Crusafont, and J Tor Aquilera, and R Muga Bustamante
Production of monoclonal antibodies to human immunodeficiency virus type-2.
December 1992, Puerto Rico health sciences journal,
V Soriano Vázquez, and A Ribera Crusafont, and J Tor Aquilera, and R Muga Bustamante
[Establishment of a double-antigen sandwich ELISA for detecting total antibodies to human immunodeficiency virus type 1/2].
September 2002, Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology,
V Soriano Vázquez, and A Ribera Crusafont, and J Tor Aquilera, and R Muga Bustamante
ELISA for herpes simplex virus type 2 antibodies.
November 1977, Lancet (London, England),
V Soriano Vázquez, and A Ribera Crusafont, and J Tor Aquilera, and R Muga Bustamante
Recombinant human antibodies against the reverse transcriptase of human immunodeficiency virus type-1.
May 2003, Biochimica et biophysica acta,
V Soriano Vázquez, and A Ribera Crusafont, and J Tor Aquilera, and R Muga Bustamante
Epitope mapping of monoclonal antibodies against human immunodeficiency virus type 1 structural proteins by using peptides.
August 1989, Journal of virology,
V Soriano Vázquez, and A Ribera Crusafont, and J Tor Aquilera, and R Muga Bustamante
Human immunodeficiency virus type 2.
June 2002, The Journal of general virology,
Copied contents to your clipboard!